A medication impregnated bone cement (MIBC) coated intramedullary (IM) nail for fixation of a long bone fracture comprising an IM nail base and medication impregnated bone cement. The bone cement encapsulates at least a portion of the IM nail base and forms an interface between the adjacent surfaces of the IM nail base and the bone cement. The interface between the encapsulating bone cement and the encapsulated IM nail base being enhanced to increase the adhesion of the encapsulating bone cement to the encapsulated IM nail base. The increase in adhesion being sufficient to ensure that the encapsulating bone cement remains adhered to the encapsulated IM nail base when the medication impregnated bone cement coated intramedullary nail is removed from the long bone.

An osteotomy implant includes a first surface extending generally in a first plane and a second surface extending generally in a second plane, oblique to the first plane. The first surface has a perimeter having a first linear edge, a first curve edge connected to the first linear edge, a second linear edge connected to the first curved edge, and a second curved edge connected to the second liner edge.

A pharmaceutically acceptable insulin premix formulation contains about 0.1-10.0 Unit/mL of insulin for intravenous administration and preferably further contains a tonicity adjuster. The methods for making and using such formulation are also provided. The pharmaceutically acceptable insulin premix formulation may be aseptically filled into a flexible container assembly to form a pharmaceutical insulin premix product. The insulin premix product can be a sterile and ready-to-use aqueous solution for glycemic control in an individual with metabolic disorders through intravenous infusion. The insulin premix product is unexpectedly stable when freshly prepared and also during its shelf-life of storage at refrigeration temperatures of 2° C. to 5° C. for 24 months followed by additional 30 days at room temperatures of 23° C. to 27° C., even without any added preservative, any added zinc, any added surfactant or any other added stabilizing excipient.

A pharmaceutically acceptable insulin premix formulation contains about 0.1-10.0 Unit/mL of insulin for intravenous administration and preferably further contains a tonicity adjuster. The methods for making and using such formulation are also provided. The pharmaceutically acceptable insulin premix formulation may be aseptically filled into a flexible container assembly to form a pharmaceutical insulin premix product. The insulin premix product can be a sterile and ready-to-use aqueous solution for glycemic control in an individual with metabolic disorders through intravenous infusion. The insulin premix product is unexpectedly stable when freshly prepared and also during its shelf-life of storage at refrigeration temperatures of 2° C. to 5° C. for 24 months followed by additional 30 days at room temperatures of 23° C. to 27° C., even without any added preservative, any added zinc, any added surfactant or any other added stabilizing excipient.

Staple cartridge assemblies for use with surgical stapling instruments and methods for manufacturing the same are provided. Scaffolds for use with a surgical staple cartridge and methods for manufacturing the same are also provided.

Biodegradable magnesium alloy implantable medical devices are protected to delay onset of corrosion, and thus biodegradability, or to corrode more uniformly. The protection allows for extended effective use of the devices while maintaining biodegradability. Examples of protective coatings include conversion coatings that at least partially remove exposed second phases from a surface of the magnesium alloy and coatings that provide a barrier between water and the surface of the magnesium alloy.

Described herein is a generalized injection device for delivering formulations of various mechanical properties to precise locations. Of particular interest is the manifestation intended for the application of a thermally responsive hydrogel to the tear duct for the purpose of occlusion, as a treatment for symptoms associated with dry eye syndrome. Further, a modular solution to the need for an injection device across a variety of applications, mechanism, and physical considerations is provided. This disclosure provides examples of methods for precise injection of low volumes, moisture retention in pre-filled injection devices, and actuation for automatic or manual injection, to name a few.

A drug-loaded implanted medical device (10) and a preparation method therefor. The drug-loaded implanted medical device (10) comprises a device body (100), a hydrophilic coating layer (200) loaded on the device body (100), and crystalline drug particles (300) loaded on the hydrophilic coating layer (200). The hydrophilic coating layer (200) comprises a graft polymer containing a photo-crosslinked group. The medical device (10) uses a hydrophilic coating layer (200) as a carrier, effectively avoiding the risk of embolism, encouraging the crystalline drug particles to fall off, and helping to achieve a target tissue concentration. The invention can also effectively increase the anchoring effect between the carrier and the device, and reduce toxicity.

Shape memory alloys are used in aerospace structures, orthodontics, cardiovascular prosthetic devices, sensors and controllers, and many other engineering, technology, science, and other fields. The methods are described in the case of a temporary heart assist pump to illustrate the concepts, but the method applies to many other fields. The properties of shape memory alloys are used to fold or collapse and implant in the human body a device without breaking the device as it reaches body temperature or without reaching permanent plastic deformation. The properties of nitinol are also used to describe intended explantation of the device, at body temperature, from the body without breaking it. Such planned explantation may be needed in cases where the device is designed for temporary use, such as mechanical circulatory support devices intended for temporary use and then removal of all components of the device from the body. The same method can be used for devices that have not been initially designed for removal, such as stents or valves, that must later be explanted for reasons unanticipated when they were installed. The methods ensure that the devices stay within stress-strain-temperature conditions so they remain elastic, or under the upper stress plateau, or remain plastic, but always under the breaking strain, of shape memory alloys at: room or environmental conditions; cooler than environmental conditions; and at a higher temperature, or body temperature. The methods described may also be applied to other industrial applications, where shape memory alloys may be installed and removed at different temperatures. Applications in other industries, include aerospace, civil structures, mechanical structures are contemplated.

Biodegradable magnesium alloy implantable medical devices are protected to delay onset of corrosion, and thus biodegradability, or to corrode more uniformly. The protection allows for extended effective use of the devices while maintaining biodegradability. Examples of protective coatings include conversion coatings that at least partially remove exposed second phases from a surface of the magnesium alloy and coatings that provide a barrier between water and the surface of the magnesium alloy.